Niacin-based therapy for dyslipidemia: Past evidence and future advances

American Journal of Managed Care

Volumn 8, Issue 12 SUPPL., 2002, Pages

  Ito, Matthew K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VITAMIN;

ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; COST BENEFIT ANALYSIS; DISEASE COURSE; DISORDERS OF LIPOPROTEIN METABOLISM; DOSE CALCULATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MYOPATHY; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; TABLET; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NIACIN; TRIGLYCERIDES; UNITED STATES;

EID: 0036737525     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel III Report. Bethesda, Md: National Heart, Lung, and Blood Institute; 2001. Publication No. 01-3095.
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
3. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M):M8-M14.
4. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Münster (PROCAM) Study. Eur J Epidemiol. 1992; 8(suppl 1):99-103.
5. Libby P. Atherosclerosis: the new view. Sci Am. 2002;286:46-55.
6. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992;38:1632-1638.
7. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
9. Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78:572-575.
10. Nyman JA, Martinson MS, Nelson D, et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Arch Intern Med. 2002;162: 177-182.
11. Kuvin JT, Ramet ME, Patel AR, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144:165-172.
12. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
13. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
14. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097-1104.
15. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
16. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am Coll Cardiol. 1986;8:1245-1255.
17. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
18. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568-1576.
19. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
20. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
21. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
23. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
24. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
25. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
26. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
28. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am. 2000;84:23-42.
29. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998;158:577-584.
30. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis 1. N Engl J Med. 2002;346:539-540.
31. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
32. Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol. In press.
33. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation in patients with dyslipidemia. Am J Cardiol. 2002;89:672-678.
34. Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis. 2002;151:135.